Clarivate (NYSE:CLVT) Issues FY 2026 Earnings Guidance

Clarivate (NYSE:CLVT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.700-0.800 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.4 billion.

Clarivate Stock Down 1.4%

NYSE CLVT opened at $2.32 on Thursday. The stock has a market capitalization of $1.53 billion, a PE ratio of -7.72 and a beta of 1.51. Clarivate has a 1 year low of $1.66 and a 1 year high of $4.77. The company has a debt-to-equity ratio of 0.90, a current ratio of 0.87 and a quick ratio of 0.87. The business’s 50-day moving average is $2.77 and its 200 day moving average is $3.46.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CLVT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research note on Monday, December 29th. Barclays lowered their target price on shares of Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a report on Wednesday. The Goldman Sachs Group lowered Clarivate from a “buy” rating to a “neutral” rating and dropped their target price for the company from $4.20 to $3.60 in a research report on Thursday, January 8th. Morgan Stanley reiterated an “underweight” rating and issued a $3.00 target price (down from $5.00) on shares of Clarivate in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Four equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $3.30.

Insider Buying and Selling at Clarivate

In related news, insider Bar Veinstein sold 309,902 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $3.74, for a total value of $1,159,033.48. Following the transaction, the insider directly owned 848,811 shares of the company’s stock, valued at $3,174,553.14. This represents a 26.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 23.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Clarivate

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jump Financial LLC acquired a new stake in Clarivate during the fourth quarter valued at $41,000. PharVision Advisers LLC purchased a new stake in shares of Clarivate during the 3rd quarter worth about $45,000. Pitcairn Co. purchased a new stake in shares of Clarivate during the 2nd quarter worth about $52,000. RPO LLC purchased a new position in Clarivate during the fourth quarter worth approximately $64,000. Finally, Corsair Capital Management L.P. acquired a new position in shares of Clarivate during the 4th quarter worth approximately $67,000. Institutional investors and hedge funds own 85.72% of the company’s stock.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.